Abstract

Ferroptosis, which is characterized by the accumulation of intracellular iron and subsequent lipid peroxidation, is a newly discovered form of regulated cell death and plays an important role in tumor suppression. Herein, we showed that Polyphyllin III, which is a major saponin extracted from Paris polyphylla rhizomes, exerted its proliferation-inhibitory effect on MDA-MB-231 triple-negative breast cancer cells mainly through ACSL4-mediated lipid peroxidation elevation and ferroptosis induction. ACSL4 deletion partly attenuated Polyphyllin III-induced ferroptosis. Polyphyllin III treatment also induced KLF4-mediated protective upregulation of xCT, which is the negative regulator of ferroptosis. Interestingly, combination with the xCT inhibitor sulfasalazine (SAS) or downregulation of KLF4 sensitized MDA-MB-231 cells to Polyphyllin III. Furthermore, in vivo xenograft models, SAS significantly sensitized MDA-MB-231 breast cancer cells to Polyphyllin III, likely by enhancing intracellular lipid peroxidation and ferroptosis. The results of this study collectively demonstrated that Polyphyllin III exerts its anticancer effect by inducing ferroptosis via ACSL4 in MDA-MB-231 breast cancer cells. More importantly, we observed for the first time that KLF4-mediated xCT upregulation serves as negative feedback during ferroptosis progression, which might contribute to drug resistance in cancer treatment.

Highlights

  • Breast cancer is one of the most common cancers among women worldwide, with an estimated 2.1 million new cases in 2018 (Bray et al, 2018)

  • Our results showed that Polyphyllin III exerted anticancer activities against MDA-MB-231 cells mainly via ferroptosis induction mediated by Acyl-CoA synthetase long-chain family member 4 (ACSL4)

  • The results showed that only the ferroptosis inhibitors Fer-1, Lipo1, and CPX could significantly improve the cellular viability, while the others could not (Figure 1C)

Read more

Summary

Introduction

Breast cancer is one of the most common cancers among women worldwide, with an estimated 2.1 million new cases in 2018 (Bray et al, 2018). According to the National Cancer Institute, there were 276,480 estimated new cases and 42,170 estimated deaths of breast cancer in the United States in 2020 (National Institutes of Health, 2021). Breast cancer is a highly heterogeneous tumor that requires individualized comprehensive treatment. Treatments of breast cancer include surgery, radiotherapy, endocrine therapy, Polyphyllin III-induced ferroptosis in TNBC chemotherapy, targeted therapy, etc. TNBC is regarded as a more aggressive, more invasive, and harder-to-treat breast cancer, which in turn affects its survival rate and life expectancy. Using chemotherapy to treat triple-negative breast cancer is still an effective option

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.